GLP-1 – Medxy AI

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet

By MedXY 09/17/2025

A fermentable carbohydrate-enriched diet combined with metformin improves postprandial glycaemia, enhances GLP-1 secretion, and positively alters gut microbiota in prediabetic individuals, offering a personalized nutrition-pharmacology strategy for diabetes prevention.

Clinical Updates Wellness & Lifestyle

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

By MedXY 09/07/2025

A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.

Clinical Updates Wellness & Lifestyle

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

By MedXY 08/22/2025

A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.

Clinical Updates Wellness & Lifestyle

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

By MedXY 08/22/2025

The ADA's 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.

Clinical Updates Wellness & Lifestyle

Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes

By MedXY 08/17/2025

Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabetic patients.

Clinical Updates Wellness & Lifestyle

GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis

By MedXY 07/30/2025

GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.

Wellness & Lifestyle

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

By MedXY 07/28/2025

Semaglutide drugs like Ozempic and Wegovy are transforming obesity treatment, but questions remain about long-term safety, access, and societal impact.

Wellness & Lifestyle

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

By MedXY 07/28/2025

Exploring the science, benefits, risks, and realities behind Ozempic and other GLP-1 drugs in the fight against obesity.

Wellness & Lifestyle

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

By MedXY 07/25/2025

New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.